Background: Breast cancer is a heterogeneous disease characterized by differential responses to targeted and chemotherapeutic agents. Antibody-drug conjugates are one of the promising strategies for the treatment of breast cancer. Monomethyl auristatin E (MMAE) is a highly potent microtubule inhibitor and a common payload used for development of antibody-drug conjugates. The purpose of this study was to investigate the cytotoxic effects of MMAE on breast cancer cell lines.Materials and Methods: MDA-MB-468 and MDA-MB-453 cells were treated with MMAE at various concentrations (1, 10, 100, and 1000 ng/ml), and cytotoxicity was measured after 48 and 72 hours using an MTT assay.Results: Our findings indicated that MMAE possesses dose- and time-d...
Auristatins are a class of ultrapotent microtubule inhibitors, whose growing clinical popularity in ...
Antibody-drug conjugates (ADCs), designed to selectively deliver cytotoxic agents to antigen-bearing...
Abstract Antibody‐drug conjugates (ADCs) belong to a promising class of biopharmaceuticals in which ...
Targeted therapy using specific monoclonal antibodies (mAbs) conjugated to chemotherapeutic agents o...
Background: Monomethyl auristatin E (MMAE) is a synthetic analog of dolastatin 10, a compound origin...
Targeted therapy using specific monoclonal antibodies (mAbs) conjugated to chemotherapeutic agents o...
A promising approach for the development of high-affinity tumor targeting ADCs is the use of enginee...
Background Trastuzumab, a humanized monoclonal antibody targeting Human Epidermal growth factor Rece...
Background: Trastuzumab, a humanized monoclonal antibody targeting Human Epidermal growth factor Rec...
Antibody-drug conjugates (ADCs) have recently emerged as efficient and selective cancer treatment th...
Pancreatic cancer is one of the most lethal malignancies. Treatment with the first-line agent, gemci...
Intrinsic tumor resistance to radiotherapy limits the efficacy of ionizing radiation (IR). Sensitizi...
poster + "pitch" de présentation du poster de 90sposter + "pitch" de présentation du poster de 90sTh...
Rationale: Platelets are increasingly recognized as mediators of tumor growth and metastasis. Hypoth...
Antibody-drug conjugates (ADCs) are consisted of the combination of highly specific monoclonal antib...
Auristatins are a class of ultrapotent microtubule inhibitors, whose growing clinical popularity in ...
Antibody-drug conjugates (ADCs), designed to selectively deliver cytotoxic agents to antigen-bearing...
Abstract Antibody‐drug conjugates (ADCs) belong to a promising class of biopharmaceuticals in which ...
Targeted therapy using specific monoclonal antibodies (mAbs) conjugated to chemotherapeutic agents o...
Background: Monomethyl auristatin E (MMAE) is a synthetic analog of dolastatin 10, a compound origin...
Targeted therapy using specific monoclonal antibodies (mAbs) conjugated to chemotherapeutic agents o...
A promising approach for the development of high-affinity tumor targeting ADCs is the use of enginee...
Background Trastuzumab, a humanized monoclonal antibody targeting Human Epidermal growth factor Rece...
Background: Trastuzumab, a humanized monoclonal antibody targeting Human Epidermal growth factor Rec...
Antibody-drug conjugates (ADCs) have recently emerged as efficient and selective cancer treatment th...
Pancreatic cancer is one of the most lethal malignancies. Treatment with the first-line agent, gemci...
Intrinsic tumor resistance to radiotherapy limits the efficacy of ionizing radiation (IR). Sensitizi...
poster + "pitch" de présentation du poster de 90sposter + "pitch" de présentation du poster de 90sTh...
Rationale: Platelets are increasingly recognized as mediators of tumor growth and metastasis. Hypoth...
Antibody-drug conjugates (ADCs) are consisted of the combination of highly specific monoclonal antib...
Auristatins are a class of ultrapotent microtubule inhibitors, whose growing clinical popularity in ...
Antibody-drug conjugates (ADCs), designed to selectively deliver cytotoxic agents to antigen-bearing...
Abstract Antibody‐drug conjugates (ADCs) belong to a promising class of biopharmaceuticals in which ...